Prenetics Global Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M

Reuters

2025/06/18

<a href="https://laohu8.com/S/PRE">Prenetics Global</a> Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M

Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-032019), on June 18, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2544970695"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2544970695\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2544970695?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-18 21:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2544970695","market":"fut","top_or_hot":-1,"title":"Prenetics Global Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRE\">Prenetics Global</a> Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-032019), on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Prenetics Global Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPrenetics Global Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-06-18 21:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRE\">Prenetics Global</a> Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-032019), on June 18, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRE","symbol_name":"Prenetics Global","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250618:nNDL4w9JlF:1","article_id":"2544970695","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2544970695","pubTimestamp":1750252343,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"PRE":"Prenetics Global"},"translate_title":"Prenetics Global Ltd.报告2025年第一季度收入同比增长336.5%，将全年指引上调至80-1亿美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRE":0.9},"content_text":"Prenetics Global Ltd. Reports 336.5% YoY Revenue Increase in Q1 2025, Raises Full-Year Guidance to $80-100M\n    \n\n        Prenetics Global Ltd. has reported its financial results, highlighting a significant quarter-over-quarter growth. The company's Q1 revenue was reported at $5.7 million, with a projected Q2 revenue of $8.5 million, marking a 50% increase. Post-divestment of ACT Genomics, Prenetics now focuses on its three consumer health brands: IM8, CircleDNA, and Europa. The divestment has bolstered Prenetics' financial standing, with pro-forma cash reserves reaching approximately $86 million and pro-forma cash and short-term assets totaling $117 million. The company remains debt-free, enhancing its opportunities for shareholder value. Additionally, Prenetics holds a 35% stake in early cancer detection company Insighta, valued at $70 million. The company is exploring innovative treasury management strategies, including digital asset adoption and Bitcoin treasury strategies.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Prenetics Global Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-25-032019), on June 18, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport,event,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}